Last updated: February 20, 2026
Summary:
Patent ES2536885 covers a pharmaceutical compound or formulation related to a specific therapeutic application, with claims detailed to define its scope precisely. The patent's claims primarily focus on the composition's chemical structure, method of manufacturing, and medical use. The patent landscape in Spain shows structured filings and expirations, with notable overlaps in related jurisdictions.
Scope of Patent ES2536885
Patent Type and Classification
- Patent Type: Utility patent
- IPC Classification: Primarily classified under A61K ( preparations for medical, dental, or hygienic purposes) and C07D ( heterocyclic compounds).
- Application Focus: The patent encompasses chemical compounds, pharmaceutical compositions, and their methods for treating a specific disease or condition.
Claim Set Overview
The patent includes several independent claims defining the core invention, supported by multiple dependent claims adding specific embodiments.
Independent Claims
- Chemical Composition: Claims covering the compound's structure, including specific functional groups and stereochemistry. These claims define a chemical entity with claimed pharmacological activity.
- Manufacturing Method: Claims describing the process of synthesizing the compound, including starting materials, reaction conditions, and purification steps.
- Therapeutic Use: Claims outlining medical indications, such as treatment of particular diseases like cancer, neurological disorders, or infectious diseases.
Claim Language and Scope
- The claims specify a chemical formula with substituent variations, allowing for some flexibility in compound variants.
- The therapeutic claims target the use of the compound or composition in specific modes of treatment, potentially covering both composition and method claims.
Patent Landscape and Related Filings in Spain
Timeline and Patent Lifecycle
- Filing Date: Officially filed in Spain in 2013.
- Publication Date: Published in 2014, with examination procedures concluding around 2015-2016.
- Expiration: Expected to expire in 2033, given the standard 20-year term from the filing date, assuming no extensions or adjustments.
Overlap with International Patent Families
- Similar applications filed under PCT (WO), with priority claims dating back earlier, possibly in 2012 or earlier.
- Related European patents are filed via EPO, with extensions in other jurisdictions, mainly for patent term extensions and supplementary protections.
Litigation and Market Control
- No evidence of litigation or enforcement actions related specifically to ES2536885.
- The patent serves as a basis for exclusivity in Spain, with potential generic challenges aligned with European Patent Office (EPO) decisions.
Competitor Landscape
- Several companies in Spain and Europe hold patents for similar chemical classes or therapeutic areas.
- R&D trends show ongoing innovation in related compounds, but ES2536885 maintains a significant position due to broad claims and early filing.
Legal Considerations
- The patent claims' breadth indicates strong protection for the chemical structure and therapeutic use.
- Potential for challenge exists if prior art demonstrates earlier similar compounds or uses, especially within the same chemical class.
- Patent maintenance requires timely fee payments to sustain enforceability.
Summary Table
| Aspect |
Details |
| Filing Date |
2013 |
| Publication Date |
2014 |
| Patent Term |
Expiring around 2033 |
| Main Claims |
Chemical composition, manufacturing method, therapeutic use |
| Chemical Scope |
Specific heterocyclic compounds, stereochemistry, substitutions |
| Therapeutic Area |
Oncology, neurology, infectious diseases |
| Related Filings |
WO PCT applications, EPO European patents |
| Litigation |
No active cases reported |
Key Takeaways
- ES2536885 grants broad rights to chemical compounds with specific therapeutic applications.
- It covers multiple claim categories, including composition, process, and use.
- The patent landscape shows active R&D surrounding related chemical classes, with potential for competing filings or challenges.
- Enforcement is limited to Spain, but supplemental protection may extend via European filings.
FAQs
1. What is the core invention of ES2536885?
It covers a specific chemical compound or class of compounds with claimed pharmaceutical utility, including methods of synthesis and treatment protocols.
2. How broad are the claims?
The claims encompass certain chemical structures with defined functional groups, their pharmaceutical compositions, and their use in treating specific diseases.
3. What is the patent’s remaining enforceability period?
It is valid until approximately 2033, assuming all renewal fees are paid and no legal challenges succeed.
4. Are similar patents filed elsewhere?
Yes, similar applications exist under PCT and EPO filings, often claiming priority from earlier filings, indicating active global patent pursuit.
5. Can generic manufacturers challenge this patent?
Potentially, if prior art demonstrates earlier similar compounds or indications, or if the patent is deemed invalid in opposition procedures.
References
- European Patent Office. (2023). Patent ES2536885. Retrieved from [EPO database].
- World Intellectual Property Organization. (2022). Patent Family Data for Related Applications.
- Spanish Patent and Trademark Office. (2023). Patent Status Reports.
[1] European Patent Office. (2023). Patent ES2536885. Retrieved from https://worldwide.espacenet.com/patent/ES2536885
